Intelli Science began over thirty years ago in Spain, where a small team of scientists and regulatory professionals set out to solve a straightforward problem: the growing gap between what regulators required and what companies could operationally deliver.

Through the 1990s and into the 2000s, as European pharmaceutical regulation matured and international harmonization accelerated, the firm grew alongside its clients — building methodologies, refining processes, and earning a reputation for work that was both scientifically defensible and practically executable.

Expansion to Canada marked a pivotal chapter, adding North American regulatory depth and positioning the team to serve clients operating across multiple jurisdictions simultaneously. Working at the intersection of Health Canada, FDA, and EMA requirements sharpened a core competency that remains central to our identity: the ability to translate between regulatory systems rather than simply replicate compliance checklists.

In 2025, we reestablished our headquarters in the United States as Intelli Science. The new name carries forward three decades of institutional knowledge while signaling the next chapter — one defined by advanced analytics, AI-driven safety science, and an expanded global consulting practice. Our trajectory — from a European founding through North American expansion to a US-based firm serving clients worldwide — mirrors the increasingly borderless nature of the industry we serve.